Pfizer Posts Details About Interactions With U.S. Physicians
- Details
- Category: Pfizer
Pfizer Inc. released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines.
Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease
- Details
- Category: Novo Nordisk
Novo Nordisk, a global healthcare company and leader in diabetes care, today announced the launch of the Novo Nordisk BlueSheet, a resource for information on diabetes and chronic disease, highlighting key issues in diabetes prevention, detection, treatment and care.
Lilly USA Updates Health Education Program to Help Patients with Depression Build Network of Support
- Details
- Category: Eli Lilly and Company
The Support Partners Program offered by Lilly USA shows individuals with depression ways to build their own support group, which, in turn, can help them better deal with their depression symptoms. The Support Partners Program can also help people better understand the illness and the importance of seeking help from a health care professional.
Dabigatran etexilate shows greater reductions than warfarin
- Details
- Category: Boehringer Ingelheim
Data presented at the 59 th Annual Scientific Session of the American College of Cardiology have shown greater reductions in stroke in patients with atrial fibrillation (AF) for dabigatran etexilate* compared to the current standard of care, warfarin, irrespective of a patient's risk profile for stroke.(1)
ratiopharm to become the hub for Teva's European growth strategy
- Details
- Category: Financial
The ratiopharm Group gets a new owner. Subsequent to an extensive bidding process, the Israel-based company Teva Pharmaceutical Industries Ltd. is going to acquire the Ulm based company from Merckle Group's VEM asset management. The agreed enterprise value is € 3.625 billion.
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline has been working closely with governments around the world to respond to their pandemic needs since the start of the H1N1 pandemic. We recognise that pandemics are unpredictable and that government needs and plans have evolved as understanding of the H1N1 pandemic has increased.
Stimuvax Clinical Program Temporarily Suspended
- Details
- Category: Merck Group
Merck KGaA has temporarily suspended the clinical program for Stimuvax® (BLP25 liposome vaccine) in all recruiting studies worldwide as a result of a suspected unexpected serious adverse reaction (SUSAR).
More Pharma News ...
- Pfizer Signs Long-Term Agreement to Supply Prevenar 13 to The World's Poorest Countries
- Saudi Food and Drug Authority Suspends The Authorisation of Rosiglitazone (Avandia®)
- Abbott Completes Acquisition of STARLIMS Technologies
- Jury Rules In Favour of AstraZeneca in First US Seroquel Product Liability Trial
- Roche uniquely positioned to deliver long-term growth
- New PLATO Sub-Analysis of CABG Patients Presented at ACC
- Abbott Announces Positive Data From ABSORB Trial on Its Bioresorbable Vascular Scaffold Technology